Michael Gelband’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Michael Gelband’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,964	Closed	-$81K	–	2664
2022 Q1	$81K	Buy	+11,964	New	+$85.3K	﹤0.01%	2027
2021 Q3	–	Sell	-26,064	Closed	-$177K	–	2832
2021 Q2	$177K	Buy	26,064 +15,189	+140%	+$126K	﹤0.01%	2024
2021 Q1	$112K	Buy	+10,875	New	+$119K	﹤0.01%	1969
2020 Q3	–	Sell	-13,738	Closed	-$95K	–	2360
2020 Q2	$95K	Buy	+13,738	New	+$74.1K	﹤0.01%	1639
2020 Q1	–	Sell	-10,100	Closed	-$88K	–	1789
2019 Q4	$88K	Buy	+10,100	New	+$54.6K	﹤0.01%	1437

Other funds holding JNCE

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Michael Gelband's JNCE Position: Q2 2022 in Review

Michael Gelband sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2022, closing a stake of 11,964 shares — an estimated $81K sold.

Michael Gelband first reported a position in JNCE in Q4 2019 and held it in 5 quarters. The position peaked at $177K in Q2 2021. 102 funds tracked by Wall St. Rank hold JNCE as of Q2 2022.

Michael Gelband reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Michael Gelband sold 11,964 Jounce Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $81K.
Michael Gelband first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2019 and held it in 5 quarters.
Michael Gelband's Jounce Therapeutics, Inc. Common Stock position peaked at $177K in Q2 2021.
102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.